PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has unanimously elected Christopher Boerner, Ph.D., to serve as Chair of the Board, effective April 1, 2024. He succeeds Giovanni Caforio, M.D., who will step down as Chair of the Board on April 1, 2024 and retire from the company after 23 years of service.

Boerner was named Executive Vice President, Chief Operating Officer and CEO-elect on April 26 and, as of November 1, Boerner will be Chief Executive Officer of Bristol Myers Squibb.

“I am honored to become CEO and later Board Chair,” said Boerner. “Giovanni has strengthened Bristol Myers Squibb’s legacy of innovation and pioneering new treatments. I am grateful for the tremendous impact he has had on our organization over the past 23 years.”

“It has been a privilege to help write a chapter in this company’s storied history,” said Caforio. “We have made incredible progress in discovering and delivering medicines that really matter to patients and I am confident that under Chris, Bristol Myers Squibb will continue its legacy of bringing transformational medicines to even more patients in need.”

“I want to thank and congratulate Giovanni for a successful eight-year tenure as CEO of Bristol Myers Squibb,” said Theodore R. Samuels, Lead Independent Director of Bristol Myers Squibb. “Giovanni will continue to excel as our Executive Chairman in ensuring a smooth transition. As Chris takes the reins as CEO, and ultimately Chair of the Board next April, he has the respect and admiration of our entire team. Bristol Myers Squibb is going from strength to strength.”

About Christopher Boerner, Ph.D.

Christopher Boerner has served as EVP, Chief Operating Officer and CEO-elect since April 26, 2023. He was appointed EVP, Chief Commercialization Officer on August 28, 2018, where he led the worldwide Commercial and Medical organizations and was responsible for driving growth across the company’s key franchises. Boerner previously served as head of international markets at Bristol Myers Squibb, accountable for international commercial activities. Prior to that, he served as head of U.S. commercial markets, responsible for U.S. sales and marketing, government affairs and market access. He joined the company in February 2015.

From 2010 to 2015, Boerner served in leadership roles of increasing responsibility at Seattle Genetics, Inc. From 2002 to 2010, he served in marketing leadership roles at Genentech, a member of the Roche Group, focused on strategy, development and commercialization across multiple oncology products and immunology. Earlier in his career, Boerner worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.

Boerner received his Ph.D. and MA in business administration from the Haas School of Business at the University of California, Berkeley, and holds a BA in economics and history from Washington University in St. Louis.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031813783/en/